What does this video actually claim?
Dubai personal trainer Khaled Aboelnor promotes a peptide "stack" of BPC-157 and TB-500 for treating "stubborn injuries." He claims BPC-157 improves blood flow to injury sites while TB-500 speeds up cellular repair, making them synergistic when combined.
His dosing recommendations include 250-500 mcg BPC-157 twice daily and 2-5 mg TB-500 weekly, split into two injections. The video presents this as established protocol for injury recovery, complete with specific timing and dosage instructions.
Does the science back this up?
The evidence is weaker than Aboelnor suggests. Most BPC-157 research comes from animal studies, not human trials. A 2022 review by Khatab et al. in the International Journal of Molecular Sciences found promising results in rats for tendon and muscle healing, but acknowledged the lack of human safety data.
TB-500 research is even thinner. The synthetic peptide mimics thymosin beta-4, which does play roles in wound healing. However, controlled human studies on TB-500 specifically are essentially nonexistent. A 2017 study by Sosne et al. in Wound Repair and Regeneration examined thymosin beta-4 in corneal healing, but that's far from validating TB-500 injections for sports injuries.
What did they get wrong?
Aboelnor presents his dosing protocol as "common" without acknowledging these peptides aren't FDA-approved for human use. The FDA has actually issued warning letters to companies selling BPC-157, noting it's not approved as a dietary supplement or drug.
His explanation of how the peptides work is oversimplified. While BPC-157 may influence angiogenesis in animal models, describing it as simply "opening pathways for blood" misrepresents the complex mechanisms involved. The synergy claim between BPC-157 and TB-500 isn't supported by any published combination studies.
Most problematically, he's giving specific medical dosing advice without mentioning legal status, potential side effects, or the experimental nature of these compounds.
What's the regulatory reality?
Both peptides exist in a legal gray area. The World Anti-Doping Agency banned TB-500 in 2010, listing it as a prohibited substance for athletes. BPC-157 isn't explicitly banned but would likely fall under prohibited peptide categories.
In the US, neither peptide is approved by the FDA for human use. Some compounding pharmacies offer them, but this doesn't equal safety validation. The lack of standardized manufacturing means purity and potency can vary significantly between sources.
Australia's Therapeutic Goods Administration has been particularly aggressive in cracking down on these peptides, issuing multiple warnings about unregistered products.
What should you actually know?
If you're dealing with persistent injuries, proven treatments exist. Physical therapy, corticosteroid injections, and platelet-rich plasma therapy all have human clinical data supporting their use. A 2019 systematic review by Moraes et al. in the American Journal of Sports Medicine found PRP effective for certain tendon injuries.
The peptide research isn't worthless, but it's preliminary. Animal studies showing tissue repair don't automatically translate to human benefits, especially at the doses being used recreationally. Without proper clinical trials, we don't know optimal dosing, long-term effects, or which injuries might actually benefit.
Before considering experimental peptides, exhaust evidence-based treatments first. Your money and health are better served by therapies with actual human trial data behind them.